ConcertAI, a leading provider of oncology real-world evidence and AI-driven SaaS solutions, has introduced Accelerated Clinical Trials, or ACT, a new enterprise platform that uses agentic artificial intelligence to streamline and optimize the full clinical trial process. The platform was unveiled at the 2026 Summit for Clinical Ops Executives in Orlando. ACT combines proprietary and real-world data with advanced AI workflows to help sponsors and contract research organizations shorten trial timelines by up to 20 months, lower costs, and bring treatments to patients more quickly.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
Clinical trials are increasingly complex, with challenges in patient recruitment, protocol design, and fragmented data sources. Research from the Tufts Center for the Study of Drug Development shows that over 75 percent of Phase I-IV trials require amendments, often adding months and substantial costs. ACT aims to address these challenges by creating a fully integrated, intelligent trial ecosystem. By using AI-driven probability modeling, the platform helps trial teams anticipate bottlenecks, optimize trial design, and increase the likelihood of meeting enrollment goals and study outcomes.
Eron Kelly, Chief Executive Officer of ConcertAI, explained that inefficiencies in clinical trials not only increase costs but also delay patients’ access to new therapies. He stated that trial teams need an end-to-end solution that can provide guidance, identify risks, and automate repetitive processes. According to Kelly, ACT delivers on that need by offering visibility and actionable insights across the entire trial lifecycle.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
Built on ConcertAI’s proprietary CARAai platform, ACT uses intelligent agents and specialized AI assistants to automate tasks including literature review, protocol drafting, competitive trial analysis, site feasibility assessments, site selection, and patient matching. The platform has been recognized by Frost & Sullivan as a leading AI clinical trial automation solution for 2026, highlighting its ability to integrate real-world data and agentic AI to expedite patient screening and trial execution.
ACT’s agents pull from both real-world and proprietary data sources, enabling teams to complete complex tasks faster and with greater accuracy. For clinical development, the platform can reduce study design timelines by up to 50 percent and cut the need for costly protocol amendments by roughly half. Operationally, site activation, recruitment, and selection are accelerated by 25 to 50 percent using automated validation processes.
With the launch of ACT, ConcertAI positions itself as a transformative partner for life sciences organizations, helping them deliver clinical trials more efficiently, reduce operational challenges, and bring therapies to patients faster while maintaining high standards for quality and accuracy.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
